Monitor continued operational improvement and FDA updates on Hyalofast and Cingal. Maintained guidance and strong adjusted EBITDA suggest restructuring traction, but GAAP loss widening remains a concern. The stock may trade on adjusted profitability improvement rather than GAAP EPS miss.
Price Chart
Executive Summary
Anika Therapeutics reported Q1 2026 revenue of $29.6M, up 13% YoY and beating consensus of $28.1M, but GAAP EPS of -$0.37 missed the -$0.21 consensus by 76%, driven by $4.9M in one-time severance costs. Adjusted EBITDA surged to $4.3M from $0.1M and guidance was maintained, while two directors resigned effective at the annual meeting.
Key Financial Metrics
Key Facts
- Q1 revenue $29.6M, +13% YoY, beat consensus $28.1M
- GAAP diluted EPS from continuing ops -$0.37 vs consensus -$0.21 (miss)
- Adjusted diluted EPS $0.27 vs -$0.06 prior year
- Gross margin 64.2%, up 810 bps YoY from 56.1%
- Adjusted EBITDA $4.3M vs $0.1M prior year
- FY2026 guidance maintained: revenue $114-$122.5M
- $15M share repurchase completed at avg $10.76/share
- Two directors resign, board to shrink from 9 to 7 members
Financial Impact
Revenue beat of ~$1.5M (5.4%) vs consensus; EPS miss of $0.16 (-76%) vs consensus
Risk Factors
- GAAP loss per share widened to -$0.37 from -$0.28
- One-time severance costs of $4.9M obscuring underlying profitability
- FDA approval uncertainty for Hyalofast PMA and Cingal NDA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-002799 |
| Document: f8k_042926.htm | 0001171843-26-002799 |
| Document: 0001171843-26-002799-index-headers.html | 0001171843-26-002799 |
| Document: 0001171843-26-002799-index.html | 0001171843-26-002799 |
| Document: 0001171843-26-002799.txt | 0001171843-26-002799 |
| 8-K Data (Synthetic) | 0001171843-26-002799 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 8-K | $16.17 $21.68 | ▲ +34.08% | ▲ +29.06% | $19.10 (+18.12%) |
Jul 14, 2026 11w ago | 8-K | $15.93 $22.03 | ▲ +38.29% | ▲ +35.95% | $19.10 (+19.90%) |
Jun 23, 2026 14w ago | 8-K | $14.73 $15.01 | ▲ +1.90% | ▼ −0.03% | $19.10 (+29.67%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.72 $15.60 | ▼ −5.98% | ▼ −4.20% | $19.10 (−29.76%) |
Jun 8, 2026 16w ago | DEFA14A | $14.60 $16.03 | ▲ +9.79% | ▲ +8.16% | $19.10 (+30.82%) |
Jun 1, 2026 17w ago | DEFA14A | $14.63 $14.63 | · 0.00% | ▲ +1.30% | $19.10 (+30.55%) |
Apr 30, 2026 22w ago | Insider Cluster | $12.45 $14.90 | ▲ +19.68% | ▲ +14.71% | $19.10 (+53.41%) |
Apr 29, 2026 22w ago | 8-K | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 28, 2026 22w ago | DEFA14A | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 15, 2026 24w ago | Press Release | $15.39 $14.80 | ▼ −3.83% | ▼ −9.65% | $19.10 (+24.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access